Apnimed’s Second Core Sleep Apnea Drug Candidate, AD504, Lowers AHI
“This study reinforces the potential of AD504 as a follow on to our lead product AD109,” says Larry Miller, MD, Apnimed CEO, in a release.
Read More“This study reinforces the potential of AD504 as a follow on to our lead product AD109,” says Larry Miller, MD, Apnimed CEO, in a release.
Read MoreMedtrade, a medical equipment trade event, will take place at the Kay Bailey Hutchison Convention Center in downtown Dallas.
Read MoreSleepGlad has launched a physician referral network that allows sleep centers, physicians, and HME providers to collaborate.
Read MoreNDX’s nearly 40,000-sq-ft headquarters includes corporate offices, a dental lab, a fully operational dental suite, and an education center.
Read MoreCamarillo, Calif-based Green Pharmaceuticals Inc is voluntarily recalling lot 2373/21222 of SnoreStop NasoSpray.
Read More